Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature
Ottavia Bernocchi(University of Trieste), Daniele Generali(University of Trieste), Giandomenico Roviello(University of Florence), Maria Rosa Cappelletti(University of Trieste), Valeria Cervoni(University of Trieste), Nicoletta Ziglioli(Istituti Ospitalieri di Cremona), Andrea Macchiavelli, Marianna Sirico(Istituti Ospitalieri di Cremona), Carla Strina(Istituti Ospitalieri di Cremona), Silvia Paola Corona(Hôpital Cardiologique du Haut-Lévêque), Manuela Milani(Humanitas University), Giuseppina Ferrero(Istituti Ospitalieri di Cremona)
Cited by 12
Related Papers
The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib
|Cancer Research|2009|298
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer
|Clinical Cancer Research|2006|244
Effects of Acute versus Chronic Hypoxia on DNA Damage Responses and Genomic Instability
|Cancer Research|2010|205